Molecular Partners' Radio-DARPin MP0712, targeting DLL3, is set to begin first-in-human trials in 2025, marking a key advancement in targeted cancer therapy.
The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.